Hosted on MSN
Novo Nordisk and Hims & Hers Health resolve patent dispute and collaborate on weight loss medications
Novo Nordisk has resolved its patent infringement lawsuit against telehealth provider Hims & Hers, entering into a collaboration to distribute Novo Nordisk’s weight loss medications through the Hims ...
24/7 Wall St.
Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors ...
Chattanooga Times Free Press
Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...
Insider Monkey
Hims & Hers (HIMS) Sees Analyst Optimism Following Novo Resolution
Hims & Hers Health, Inc. (NYSE:HIMS) is one of the 11 Best Day Trading Stocks to Buy Now. Investment bank Barclays discussed Hims & Hers Health, Inc. (NYSE:HIMS)’s shares on March 11th. It raised the ...
Seeking Alpha
Hims & Hers: The Novo Nordisk Deal Changes Everything
The Novo Nordisk partnership legitimizes Hims & Hers’ business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY) ...